ArticleMolecular pain
Combination of GABA-derived short peptides and pregabalin in neuropathic pain: In vivo and in silico evaluation.
Article in Molecular pain. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuropathic pain is a significant clinical issue due to the limited efficacy and adverse effects of existing therapies. This study evaluated the antinociceptive effects of the GABA-derived short peptides pyroglutamylGABA, pyroglutamylGABA ethyl ester, and pyroglutamyl diGABA in combination with pregabalin in a rat model of neuropathic pain induced by chronic constriction injury. Pain-related behavior was assessed using the hot plate test by recording changes in the latency and frequency of licking, jumping, and locomotor activity. Co-administration of peptide-pregabalin combinations modulated nociceptive responses compared with control animals in a time- and compound-dependent manner. The combination of pyroglutamylGABA with pregabalin was associated with increased licking latency and reduced licking frequency, particularly at early time points after injury. The pyroglutamylGABA ethyl ester-pregabalin combination produced the most pronounced effects on jumping-related parameters. A delay in movements was recorded when a combination of pyroglutamyl diGABA and pregabalin was used, whereas all combinations demonstrated increased locomotor activity, suggesting that the antinociceptive effects were not accompanied by the motor suppression typically associated with pregabalin treatment. To explore the potential mechanisms, molecular docking studies were performed targeting key GABAergic system components, including the GAT1 transporter, GABA-AT enzyme, and GABA-B receptors. The investigated peptides demonstrated favorable binding affinities across these targets, suggesting that potential interactions with multiple targets are involved in GABAergic neurotransmission. These findings indicate that the combinations of GABA-derived peptides with pregabalin could be an effective approach in neuropathic pain management. However, further investigation is required to validate these effects and clarify the underlying mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.